In the heart, timing isn’t a detail. It’s what turns separate contractions into a single heartbeat. Guli brings that same timing to T45 Labs. A single board meeting means coordinating a dozen calendars, 10-12 executives, each with their own time zone and priorities. As she put it, “Finding a time that works isn’t luck — it’s strategy.” She draws the moving parts together, gives each priority its place, and keeps the work flowing. Nearly two years in, her judgment, warmth, and presence have become part of the company’s rhythm. Things connect. Loose ends get picked up. The right conversation happens at the right moment. None of it is loud, but it’s the kind of steady presence you only notice when it’s missing. #T45Labs #MedTech #EmployeeSpotlight #Operations #ExecutiveAssistant
T45 Labs
Medical Equipment Manufacturing
Building and Funding the Next-Generation Cardiovascular Innovations
About us
T45 Labs is a Silicon Valley-based medtech incubator and investment platform that builds acquisition-ready cardiovascular companies. We reduce development risk by advancing differentiated technologies through critical clinical and regulatory milestones. T45 Labs follows a best-follower strategy: entering validated markets, refining early concepts, and focusing on outcomes, ease of use, and cost efficiency. Through T45 Fund-I and T45 Fund-II, we partner with physicians and entrepreneurs to build differentiated cardiovascular companies with clear paths to strategic acquisition and attractive investor returns.
- Website
-
www.t45labs.com
External link for T45 Labs
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Santa Clara
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
Santa Clara, Headquarters, US
Employees at T45 Labs
Updates
-
We’re pleased to welcome Mansi Gunjal to T45 Labs as our new Staff Accountant. Mansi has more than four years of accounting and audit experience covering full-cycle accounting, financial reporting, reconciliations, month-end close, and audit support. She recently completed a master’s degree in Accounting and Data Analytics at Seattle University. In her new role, Mansi will support the Accounting and Finance Team across T45 Labs and its portfolio companies. Welcome to the team, Mansi! #T45Labs #TeamT45 #Accounting #Finance #NewHire
-
-
Emmanuel Makinde joins T45 Labs as IT Operations & Support Engineer. His experience spans Microsoft 365, Azure, InTune, device management, and technical support, built through roles at Netflix, Cupertino Electric, Inc., and Insight Global. At T45 Labs, Emmanuel will help keep the systems, devices, and tools behind the work running smoothly. Glad to have you with us, Emmanuel. #T45Labs #MedTech #NewHire
-
-
We welcome Marianne Hadre to T45 Labs as Senior Operations Manager. Marianne has nearly two decades of experience in people leadership and operations, shaped by her previous roles at One Medical and Macy's’. She has a track record of managing complex day-to-day operations, leading teams, and supporting new office openings. At T45 Labs, Marianne will help keep the office running smoothly, the details moving, and the team supported. Welcome aboard, Marianne. #T45Labs #Operations #TeamT45
-
-
Last year, we described America as the original startup. There was no blueprint or guarantees, only belief, grit, and timing. Now, 250 years later, it remains an experiment that everyone wants to be part of. Here's to everyone building alongside us. Happy 4ᵗʰ of July, from all of us at T45 Labs. #T45Labs #FourthOfJuly #America250 #MedTech #CardiovascularInnovation
-
-
Congratulations to the Advanced NanoTherapies team for completing enrollment in ADVANCE-DUO, a 35-patient European study of SirPlux Duo conducted at three leading interventional cardiology centers in Spain. Unlike first-generation DCBs, which deliver a single drug, ANT's platform uses functionalized nanoparticles to deliver two drugs simultaneously. This study, aligned with the planned U.S. pivotal protocol, provides clinical experience that will directly inform the trial. #ANT #SirPluxDuo #DrugCoatedBalloon #InterventionalCardiology #VascularIntervention #ClinicalTrials #MedTech
Advanced NanoTherapies has completed enrollment in ADVANCE-DUO, its 35-patient European study of SirPlux™ Duo conducted across three leading interventional cardiology centers in Spain. Designed to mirror the planned U.S. pivotal protocol, ADVANCE-DUO builds the clinical experience that will carry directly into the trial. SirPlux™ Duo is the first drug-coated balloon to simultaneously deliver sirolimus and paclitaxel via a functionalized nanoparticle platform, exclusively licensed from Cleveland Clinic. We thank the investigators and study teams at all three centers: Dr. Omar Abdul-Jawad Altisent, Hospital Clínic de Barcelona Dr. Víctor Alfonso Jiménez Díaz, Hospital Alvaro Cunqueiro, Hospital Universitario de Vigo Dr. Jose M de la Torre Hernández, Hospital Universitario "Marqués de Valdecilla". Santander. Spain Advanced NanoTherapies T45 Labs #ANT #SirPluxDuo #DrugCoatedBalloon #InterventionalCardiology #VascularIntervention #ClinicalTrials #MedTech SirPlux™ Duo is an investigational device and has not been approved for commercial use.
-
Congratulations to the Advanced NanoTherapies team on closing an oversubscribed $31M Series B round, co-led by S3 Ventures and a strategic investor. While first-generation DCBs deliver only one drug, ANT's platform uses functionalized nanoparticles to deliver two: paclitaxel for the acute response and sirolimus for the longer-term biology that drives restenosis. From an exclusive license from Cleveland Clinic to a clinical-stage platform with FDA Breakthrough Designation and a clear path to U.S. pivotal: this is the work T45 Labs was built for. Link to press release: https://lnkd.in/dPwfpbWm Advanced NanoTherapies S3 Ventures Marwan Berrada-Sounni Rishi Puri, M.D., Ph.D., F.R.A.C.P. Azeem Latib #T45Labs #ANT #SirPluxDuo #DrugCoatedBalloon #InterventionalCardiology #VascularIntervention #SeriesB #MedTech
Advanced NanoTherapies has secured $31M in an oversubscribed Series B round, co-led by S3 Ventures and a strategic investor, with continued support from T45 Fund and existing investors. This funding will advance SirPlux Duo, the first drug-coated balloon to simultaneously deliver sirolimus and paclitaxel via a functionalized nanoparticle platform. The drug-agnostic, fully biodegradable platform exclusively licensed from Cleveland Clinic has received FDA Breakthrough Device Designation for three indications and is designed for coronary, peripheral, and future vascular applications. The first-in-human study has reached two years of follow-up, and a European feasibility study is now enrolling patients in Spain. Clinical experience with 58 patients supports the path toward a U.S. pivotal trial. The capital will scale manufacturing and advance the IDE submission for two coronary indications - in-stent restenosis and small-vessel de novo - and support a below-the-knee peripheral early feasibility study. Press release linked in comments. Advanced NanoTherapies S3 Ventures T45 Labs Cleveland Clinic Brian Smith Rishi Puri, M.D., Ph.D., F.R.A.C.P. Marwan Berrada-Sounni Azeem Latib #ANT #SirPluxDuo #DrugCoatedBalloon #InterventionalCardiology #VascularIntervention #SeriesB #MedTech
-
T45 Labs is proud to recognize an important leadership milestone for VahatiCor. Harry Rowland, Ph.D., has joined VahatiCor as Chief Executive Officer, bringing the cardiovascular medtech operating experience needed for the company’s next stage of growth. Harry joins as VahatiCor advances the A-FLUX Reducer System® for patients with Coronary Microvascular Dysfunction, enrolls patients in SERRA-I, prepares for SERRA-II, and continues building toward future clinical, regulatory, and commercial milestones. As part of this transition, VahatiCor Co-Founder Marwan Berrada-Sounni will remain with the company as a member of its Board of Directors, providing a founder's perspective and strategic continuity. Best wishes to Harry and the full VahatiCor team as they continue moving this important therapy forward. #MedTech #Cardiology #InterventionalCardiology #CMD #leadership
VahatiCor welcomes Harry Rowland, Ph.D., as Chief Executive Officer. Harry joins VahatiCor as the company advances the A-FLUX Reducer System for patients with Coronary Microvascular Dysfunction, enrolls SERRA-I, and prepares for SERRA-II. https://lnkd.in/e9ABkEfx "Harry is the right leader for VahatiCor at this pivotal stage, when breakthrough technology requires disciplined execution." — Brian Smith, Managing Director, S3 Ventures VahatiCor will attend #EuroPCR 2026 in Paris from May 19 to 22. The company will hold a scientific symposium on Wednesday, May 20, from 12:30 to 13:15 CEST in Room 241 at the Palais des Congrès. Welcome, Harry. #VahatiCor, #CMD, #MicrovascularDisease, #EuroPCR2026, #MedTech #leadership #interventionalcardiology #cardiology
-
Clinical milestones only happen when every detail moves in sync. At T45 Labs, we’re looking for a Clinical Trials Associate to support study coordination, site communication, and trial documentation across multiple breakthrough device programs. This role helps keep critical studies compliant, organized, and moving forward toward key development milestones. Full role details: https://lnkd.in/e-uFAwGM #ClinicalResearch #ClinicalTrials #MedicalDevices #ClinicalOperations #T45Labs #HiringNow
-
-
Clinical progress depends on data you can trust from start to finish. At T45 Labs, we’re hiring a Clinical Data Manager to lead data management across clinical studies and help ensure every dataset remains accurate, consistent, and ready to support development milestones. This role is central to maintaining data integrity from first patient through final analysis. Full role details: https://lnkd.in/efgUsGkZ #ClinicalResearch #ClinicalTrials #MedicalDevices #ClinicalData #T45Labs #HiringNow
-